Introduction {#Sec1}
============

Isotretinoin (13-*cis* retinoic acid, 13-*cis* RA) has been an effective treatment for acne since its introduction in 1982. This drug acts to suppress acne in multiple ways, reducing sebaceous gland secretion and size, possibly by inhibiting proliferation and inducing apoptosis of sebocytes (Nelson et al. [@CR30]) and also acting as an anti-inflammatory agent blocking the migration of polymorphonuclear leukocytes into the skin (Wozel et al. [@CR46]). It is believed to act by isomerisation to all-*trans*-RA in tissues (Shih et al. [@CR41]; Tsukada et al. [@CR45]), which then activates specific receptors for retinoic acid (Nelson et al. [@CR31]; Rochette-Egly and Germain [@CR36]). The RA receptors are members of the nuclear receptor family regulating the transcription of several hundreds of genes (Balmer and Blomhoff [@CR2]) and isotretinoin temporally regulates distinct sets of genes in a patient's skin (Nelson et al. [@CR31]).

Retinoic acid is synthesized endogenously from vitamin A and acts to regulate cell proliferation and differentiation in almost all organ systems of the body including bone, cardiovascular, immune, reproductive and excretory systems (Sporn et al. [@CR42]). The nervous system is also a target and how local synthesis of RA regulates the patterning of gene expression during central nervous system (CNS) development has been extensively studied (McCaffery et al. [@CR27]). However, less is known regarding its action in the adult CNS (Bremner and McCaffery [@CR3]).

The hippocampus is one of the few regions in which RA signaling is maintained through both embryonic development and into adulthood (Misner et al. [@CR29]). The hippocampus is essential for the generation of episodic and spatial memory, processes dependent on the RA-regulated functions of neuronal plasticity, long-term potentiation (LTP) and neurogenesis (McCaffery et al. [@CR28]). Deficiency in RA created by depletion of its substrate vitamin A leads to a reduction in the ability of rats to perform in the hippocampal-dependent radial maze task and loss of LTP (Misner et al. [@CR29]) (Cocco et al. [@CR6]), while similarly null mutation of RA receptors results in loss of both LTP and long-term depression (LTD) as well as deficits in spatial learning tasks (Chiang et al. [@CR5]). An alternative mechanism to LTP-regulating synaptic strength and plasticity, known as synaptic scaling, is also regulated by RA, although via a mechanism that does not involve transcriptional regulation (Aoto et al. [@CR1]) and likely requires translational control (Poon and Chen [@CR33]). RA is also required for neurogenesis in the hippocampus, inducing the expression of neurotrophin receptors (Takahashi et al. [@CR44]) and promoting neuronal differentiation and cell survival (Jacobs et al. [@CR22]).

The negative effects of RA on learning and memory in the rodent follow a U-curve shape, whereby RA deficiency results in a decline in learning and memory and excess similarly impairs these behaviours in both mouse (Crandall et al. [@CR8]) and rat (Dopheide and Morgan [@CR11]). This may reflect a function for RA in regulating neuronal plasticity that relies on a patterned RA distribution, as occurs in the embryonic CNS. Such patterns are highly sensitive to abnormally high or low RA (McCaffery et al. [@CR27]).

These important effects of RA in rodents suggest that high doses of RA may affect human brain function. In humans, high doses of RA are given in the form of isotretinoin (13-*cis* retinoic acid), a retinoid highly effective in acne therapy. In clinical practice, there is mounting evidence strongly suggesting a link between isotretinoin therapy and psychopathology (Kontaxakis et al. [@CR24]), although the possible link with depression and suicide (Sundstrom et al. [@CR43]) has been difficult to separate from the psychosocial effects of severe acne (Halvorsen et al. [@CR20]). The most frequent CNS adverse effect is headache (Bremner and McCaffery [@CR3]) and many reports have identified idiosyncratic adverse events that include increases in anxiety, aggression and depression (Bremner et al. [@CR4]; Bremner and McCaffery [@CR3]). Mood change is one of the most important considerations in clinical practice (Goodfield et al. [@CR18]).

The effects of isotretinoin on mood and behaviour might result from altered hippocampal function. Studies in animals have shown that treatment with 13-*cis* RA results in a reduction in hippocampal neurogenesis, a fall in performance in learning and memory tasks (Crandall et al. [@CR8]) as well as a decline in the size of the hippocampus (McCaffery et al. [@CR28]). Reduction in hippocampal size may be a key anatomical change in the brain linked to depressive disorder and possibly associated with accompanying deterioration in memory (Dere et al. [@CR9]; Fairhall et al. [@CR15]; MacQueen and Frodl [@CR26]). We therefore investigated the influence of isotretinoin on human learning and memory.

Materials and methods {#Sec2}
=====================

Aims {#Sec3}
----

The aims of this study were (a) to test the hypothesis that a course of oral isotretinoin therapy would result in decline in learning and memory as measured using the CANTAB cognitive testing battery, (b) to generate data to inform a larger study regarding sample size, test procedures and outcome measures and (c) to identify cognitive tasks to be used in future functional imaging studies.

Patients and methods {#Sec4}
--------------------

This was an open prospective observational study. As it was not considered ethical to withhold effective treatment for patients with severe acne, we adopted an open design with each subject baseline test providing the baseline for a within-subjects comparison. In a small study, variation between subjects can be high and matching controls for IQ, severity of acne and depression would require a much larger study. The study was approved by the North Scotland Research Ethics committee and conducted between 2008 and 2010.

Participants {#Sec5}
------------

We invited patients who were attending a dermatology outpatient clinic for treatment of severe acne vulgaris, aged 16 or over, in whom a clinical decision had been made to treat with isotretinoin to participate. We excluded patients with intelligence below normal who would not be able to understand the CANTAB psychometric tests, subjects with neurological disease, epilepsy or pre-existing mental health problems, pregnant females, females not taking contraceptive precautions and patients taking Dianette®, sedative or psycho-active medication.

Intervention {#Sec6}
------------

Patients were treated with isotretinoin, 0.5--1 mg/kg/day, for 3--6 months until satisfactory clearance of acne lesions was achieved. CANTAB visuospatial memory tasks, Beck's Depression Inventory (BDI) and Global Acne Grade (GAG) were assessed on three separate visits: the first immediately prior to starting isotretinoin, the second at 3 months later during isotretinoin therapy and with the final visit at 2 months after stopping therapy.

Procedure {#Sec7}
---------

We studied a limited range of cognitive tests to avoid tiring the subject and to keep testing under 1 h. If subjects were tired, they were permitted to take a break. The following CANTAB tests were performed in parallel mode and are summarized in Table [1](#Tab1){ref-type="table"}: motor screening was designed to relax the subject and introduce them to the touch screen and was given at the start of each session, delayed matching to sample (DMS) paired associate learning (PAL), pattern recognition memory (PRM) and spatial recognition memory (SRM).Table 1Summary of component cognitive tests of the CANTAB battery used for the studyVisual memory testPurposeDescriptionOutcome measuresNotesSensitive to changes inDelayed matching to sampleImmediate and delayed visual memoryAbility to remember the visual features of a complex abstract target stimulus and to select from a choice of four patterns after a variable delay.% correct20 trialsMedial temporal lobeTotal correct5 simultaneousFrontal lobeMean correct latency (simultaneous)15 with 3 different delaysTotal correctLatency measures the speed of giving a correct responseMean correct latency (All delays)low variability and good test retest correlationPaired associates learningVisuospatial memory and learningA test of the ability to learn the locations of a progressively increasing number of abstract stimuli% correctFirst trial memory score is the number of patterns correctly located at the first trial summed for all stages completedMedial temporal lobeTotal correctStage reachedTotal trials (up to 10 trials for each stage)Total errorsFirst trial memory scoreStages completed (out of 5) on first trialPattern recognition memoryVisual pattern recognition memoryA test of the ability to recognize a previously presented abstract pattern in a two-choice forced discriminatory procedure% correctMedial temporal lobeTotal correctMean correct latencySpatial recognition memorySpatial recognition memoryStimuli are presented in a series of locations followed by two-forced choice to select one appearing in same locationTotal incorrectPrimarily frontal lobe insensitive to temporal lobe% correctMean correct latency

At each visit, we recorded the dose of isotretinoin (mg/kg), any perceived subjective side effects, acne severity rated by the GAGs score and depression using the Becks inventory.

Sample size {#Sec8}
-----------

Based on a clinically meaningful change of 20% on a primary outcome measure and one-sided significance alpha = 0.025, we assumed a standard deviation of 20% in the primary outcome and had a 95% power of detecting this change with 18 patients.

Statistics {#Sec9}
----------

Statistics were performed using PASW statistics 18. Within-subject comparisons were made using repeated-measures ANOVA. Pearson's coefficient was used to examine correlations.

Results {#Sec10}
=======

Participants {#Sec11}
------------

Data were collected from 16 participants who were tested before, during and after treatment with isotretinoin and a further one who was lost to the study after treatment was completed. There were many more male than female participants (ratio of about 3:1) and the males were both significantly younger and had more severe acne. Both groups were prescribed similar doses of isotretinoin of about 0.5 mg/kg/day (Table [2](#Tab2){ref-type="table"}).Table 2Summary of participant characteristicsAge (years)Weight (kg)GAGS (baseline)Becks depression inventory (baseline)Initial dose (mg/kg)Midtreatment dose (mg/kg)Males, n = 13Mean (SD)20.62 (4.31)78.54 (14.74)31.00 (5.29)3.62 (3.69)0.46 (0.13)0.62 (0.26)Range15--2860--12021--400--110.12--0.600.17--1.04Females, n = 4Mean (SD)27.75 (3.95)63.50 (7.19)21.00 (2.36)4.25 (3.74)0.53 (0.06)0.63 (0.21)Range22--3153--6916--251--60.46--0.600.45--0.87Total, n = 17Mean (SD)22.29 (5.15)75.0 (14.69)28.65 (6.54)3.76 (3.36)0.48 (0.12)0.62 (0.24)Range15--3153--12016--400--110.12--0.600.17--1.04*t*, *p*3.09, 0.0242.76, 0.0187.51, 0.0040.635, NS0.069, NS0.016, NS

Depression {#Sec12}
----------

We first looked at whether depression, as measured by the BDI, changed during treatment. In a paired *t*-test, there were non-significant trends towards an increased BDI score with treatment (mean \[SD\] before = 3.76 \[3.36\], mean during \[SD\] = 5.76 \[4.19\], *p* = 0.071). We also looked at whether the size of dose correlated with change in BDI score. This revealed a trend towards an effect with higher dose associated with a larger change in BDI (*r* = 0.454, *p* = 0.067, *n* = 17).

Memory {#Sec13}
------

The effects of treatment on memory performance are shown in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}. A univariate repeated-measures ANOVA showed that performance stayed unchanged for DMS, SRM and PRM, though participants improved their speed on the PRM task. However, performance improved across sessions on the PAL task. Inclusion of either the BDI baseline depression score or its amount of change as a covariate did not alter the findings.Table 3Effects of treatment on memory testsBefore treatmentDuring treatmentAfter treatmentUnivariate repeated-measures ANOVA (*n* = 16)MeanSDRangeMeanSDRangeMeanSDRangedf*FP*^a^DMS total correct (all delays)13.591.27811--1513.181.3809--1513.441.20910--151.9781.3830.266SRM percent correct81.1813.7545--10082.6511.7465--10083.1310.9460--1001.745.2410.757PRM percent correct90.9310.0271--10094.115.3283--10091.938.4079--1001.962.0290.969PAL first trial memory score15.592.3212--1917.242.56213--2118.132.1314--211.6579.0650.002PAL stages completed on first trial3.590.513--43.47.7172--53.880.623--51.9813.2960.051PAL total errors13.2913.492--615.824.3050--154.504.590--161.2407.7740.009PAL total trials8.762.666--177.411.4175--116.811.425--101.4207.2960.008*DMS* delayed matching to sample, *SRM* spatial recognition memory, *PRM* pattern recognition memory, *PAL* paired associate learning^a^Greenhouse--Geiser correctionTable 4Effects of treatment on reaction times (mean correct latency)Mean baselineSDMinimumMaximumMean during treatmentSDMinimumMaximumMean after treatmentSDMinimumMaximumdf*FP*^a^DMS mean correct latency (all delays)3,0798341,7595,1212,6977121,1633,7992,7238161,3273,9631.9632.675.087SRM mean correct latency2,0025141,1353,0621,8283331,1302,5951,7353999252,3001.9042.217.130PRM mean correct latency1,8944551,1422,8731,7313041,3012,2931,5362721,1542,0281.8805.759.009Mean overall correct latency2,4095581,4793,6142,1874361,4322,9622,0644081,1872,654^a^Greenhouse--Geiser correction, univariate repeated-measures ANOVAFig. 1Effect of isotretinoin treatment on memory scores in the paired associated learning task showing: **a** total errors significantly reduced (*p* = 0.009), **b** total trials significantly reduced (*p* = 0.008)

Relationships with dose of isotretinoin {#Sec14}
---------------------------------------

Dose of isotretinoin correlated with improvement in the total trial score (*r* = 0.541, *p* = 0.025), reduction in total error rate (*r* = 0.485, *p* = 0.049) (Fig. [2](#Fig2){ref-type="fig"}) and stage completed at the first trial (*r* = 0.523, *p* = 0.031) as percentage change from baseline. There was no significant correlation between dose and percent improvement in first trial memory score (*r* = 0.366, *p* = 0.148) and average latency improvement (*r* = 0.027, *p* = 0.917).Fig. 2Scatterplot showing improvements in performance on paired associated learning task as an effect of treatment with isotretinoin showing that the reduction in errors in PAL is correlated with the dose of isotretinoin (*r* = 0.485, *p* = 0.049)

Discussion {#Sec15}
==========

Numerous behavioural studies in animal models have pointed to behavioural changes in rodents when the balance of RA is disrupted, either from exposure to excess or deficiency, as previously reviewed (Bremner et al. [@CR4]; Olson and Mello [@CR32]). These results indicate that a balance of RA in the brain must be maintained and that either too much or too little is detrimental. This study is the first to be performed to objectively determine possible alterations in learning and memory with isotretinoin treatment using a CANTAB cognitive assessment system that employs a succession of neuropsychological tests performed on a touch screen computer.

The CANTAB tests were focused on hippocampal-based learning and the study was designed with the hypothesis that isotretinoin treatment for acne would have a negative influence on learning and memory, comparing the effect of the drug on individuals before, during and after treatment. From this comparison, no significant decline was evident in any of the outcome measures for DMS, SRM and PRM although several test outcomes were relatively insensitive to a measure of improvement because all groups scored a high percentage of correct response even though there was a trend towards worsening of the self-rated depression score, and depression can affect memory and learning. It may be concluded that isotretinoin does not reduce learning and memory and our hypothesis was negated.

Remarkable, however, was the contrary finding that memory significantly improved with treatment. This was the case for the outcome measures of the PAL test and the reaction times on the PRM task. However, before we can conclude that isotretinoin improves memory, consideration needs to be given to the possibility that this is a practice effect, stemming simply from repeated performance of the test, or a placebo effect since this study was run as an open trial. Indeed the results of a recent study support our findings of improved learning performance with isotretinoin treatment (Ergun et al. [@CR13]), but their methods were unable to distinguish this from practice effects. In this new study, practice effects are unlikely to account for the observed improvement in paired associate learning for two reasons: first, the effect is specific to only one subdomain of cognitive function---other assessments do not show improvement over time, and second, each administration of the PAL uses trial-unique (fresh) cues. Furthermore, these tests were conducted at intervals that were separated by 2 and 3 months at a time and parallel versions were used. It would therefore seem unlikely that participants could benefit much from earlier experience and previous studies have not found benefits of repetition.

Fowler et al. ([@CR17]) did not find any change in PAL performance among typical controls when repeating testing five times over a period of 2 years, though participants with early dementia exhibited deterioration which was not evident on standard memory tests. Lowe and Rabbit report no change between trials separated 4 weeks apart on the PAL task (Lowe and Rabbitt [@CR25]). Furthermore, in separate studies, Porter et al., in a group of older people, and Falconer et al., in depressed patients receiving electroconvulsive therapy ECT, also found no difference in PAL as a result of repeated testing (Falconer et al. [@CR16]; Porter et al. [@CR34]).

A further indication of the direct effect of isotretinoin on learning and memory could be determined by analysis of correlation with the dose of isotretinoin. We therefore looked at whether improvements in performance on memory tasks correlated with dose of isotretinoin given during the main period of treatment. The improvement in performance in PAL showed a significant positive correlation with the maintenance dose measured in milligrams per kilogram. Such a correlation cannot be explained by either practice or placebo effects alone since the participants were not aware of their dose.

Why might isotretinoin have an enduring positive influence on learning? All-*trans* RA, to which 13-*cis* RA can be isomerized in vivo (Shih et al. [@CR41]; Tsukada et al. [@CR45]), is essential for neuronal plasticity---the capacity of individual neurons, their connections and neural circuits to adapt to a change in environment as well as form new memories. The most studied aspect of this process lies at the level of single synapses and weakens or strengthens their capacity to transmit information from neuron to neuron to either facilitate or weaken particular circuits to form or degrade memories. Evidence from studies in rodents has indicated that loss of RA or block of RA signaling via mutation of the receptor results in dramatic loss of such Hebbian plasticity, specifically through failure of LTP and also degradation of LTD (Chiang et al. [@CR5]; Cocco et al. [@CR6]; McCaffery et al. [@CR28]; Misner et al. [@CR29]). Recently, RA has been found to be involved in another form of neuronal plasticity. It was recognized that Hebbian plasticity such as LTP includes positive feedback and progressively increases its own activity. Homeostatic systems are necessary to dampen the results of such positive feedback known as homeostatic synaptic plasticity (Pozo and Goda [@CR35]). The RA signaling system provides one route for such homeostasis by direct regulation of glutamate receptors (Aoto et al. [@CR1]; Poon and Chen [@CR33]). Given that the results of this study imply that isotretinoin has a positive influence on learning and memory, this suggests that RA signaling in the human brain is suboptimal and can be improved by application of additional RA. This differs from, for instance, mouse (Crandall et al. [@CR8]) or rat (Dopheide and Morgan [@CR11]) in which application of isotretinoin, at a similar dose per body weight as used for humans, pushes RA signaling beyond the optimal point, leading to a decline in capacity to perform memory tasks. The reason for suboptimal levels in the human brain is unknown but if, as proposed, RA for the hippocampus derives from the surrounding meninges (Sakai et al. [@CR38]), then the size of the human hippocampus may limit the amount of RA reaching hippocampal neurons.

This study also points to an enduring effect of RA on human learning and memory. A third aspect of neural plasticity that may lead to longer-lasting effects of isotretinoin is hippocampal neurogenesis---the birth of new granule neurons in the dentate gyrus. The process is regulated by a number of factors including RA (Jacobs et al. [@CR22]; Takahashi et al. [@CR44]). Neurogenesis and incorporation of new neurons into hippocampal circuitry promotes several aspects of hippocampal-dependent memory or improves pattern separation, while inhibition of this process blocks spatial and object recognition memory and contextual fear conditioning (Imayoshi et al. [@CR21]; Jessberger et al. [@CR23]; Sahay et al. [@CR37]; Saxe et al. [@CR39]). Given that RA is required for neuronal differentiation and cell survival of granule neurons in the dentate gyrus, if isotretinoin promotes this process in the human hippocampus, then the increased number of new granule neurons would lead to long-lasting effects to promote learning and memory. It should be noted though that not all aspects of hippocampal-based spatial memory require neurogenesis and working memory required for a spatial task in mice has shown to be improved by inhibition of neurogenesis (Saxe et al. [@CR40]). It may be further noted that, in mouse, isotretinoin has been reported to inhibit neurogenesis (Crandall et al. [@CR8]).

This study found only moderate influence of isotretinon to improve learning and memory in a dose-dependent manner. This may be because the levels of retinoid signaling in the young adult in this study were only marginally suboptimal. This may not be the case, however, in older adults.

Studies in aged mice (21--23 months old) have found that the levels of brain RA receptors are lower than in younger animals. However, this can be reversed by the treatment of mice with RA, entirely reversing the decline in hippocampal-dependent memory in animals and restoring LTP in CA3 of the hippocampus (Enderlin et al. [@CR12]; Etchamendy et al. [@CR14]). Low levels of RA signaling may occur in Alzheimer's disease (Corcoran et al. [@CR7]; Goodman and Pardee [@CR19]) and application of RA to a transgenic animal model of Alzheimer's disease leads to improved learning and spatial memory (Ding et al. [@CR10]). It may be the case that the effects of isotretinoin to improve learning and memory in young adults may be far more marked in the elderly where RA signaling may be deficient. This may provide a promising future line of research.
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